Physician profile

Nicholas Kohn

Internal Medicine · Des Moines, IA

NPI 1922675578

$310.94

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$119.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $76.47 2022-2023 Jardiance, Emgality, Baqsimi
Boehringer Ingelheim Pharmaceuticals, INC. $70.89 2021-2023 Jardiance
Janssen Pharmaceuticals, INC $39.52 2022-2023 Xarelto
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $34.07 2021
Mylan Specialty L.P. $32.43 2021-2022
Otsuka America Pharmaceutical, INC. $22.99 2023 Rexulti
Actelion Pharmaceuticals US, INC. $19.88 2023 Opsumit, Uptravi
Dexcom, INC. $14.69 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nicholas Kohn

$310.94

in general payments reported 2019-2025

Years
2021-2023
Top company
Lilly USA, LLC

https://glasscript.com/doctor/10110532/nicholas-kohn

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.